Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has been updated to reflect a new version of the study protocol (v2.15.0) and includes the addition of specific cancer types and the collaborator's name, Merck Sharp & Dohme LLC. However, significant details regarding the study's purpose and treatment options have been removed.SummaryDifference51%
- Check35 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check71 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check92 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check100 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.